Mirion Technologies Inc Stock Price, News & Analysis

Mirion Technologies, Inc. (NYSE: MIR) will release its financial results for the fourth quarter and fiscal year ended December 31, 2021 on February 23, 2022. A conference call to discuss these results will take place on the same day at 10:00 am ET. Investors can join by calling 1-877-407-9208 or via webcast at Mirion's investor relations website. A telephonic replay will be available until March 9, 2022.

Kaman Composites – Vermont, a subsidiary of Kaman Corporation (NYSE:KAMN), has partnered with Mirion Technologies (NYSE:MIR) to expand its medical imaging program. This collaboration involves Kaman supplying surgical C-Arm tabletops, with the first deliveries scheduled for Q2 2022. Kaman Composites possesses 40 years of expertise in designing composite components and is recognized for its rigorous manufacturing standards. This partnership signifies Kaman's growing presence in the medical technology sector while maintaining its aerospace industry role.

Sun Nuclear Corporation, a subsidiary of Mirion Technologies (NYSE: MIR), has announced the full program for the 2022 QA & Dosimetry Symposium (QADS), scheduled for April 8-9 in Orlando, Florida. The event will focus on Quality and Patient Safety in Radiation Oncology, featuring six session themes and over 20 presentations. Topics include Cybersecurity in Healthcare and Practical Dosimetry. Notably, the symposium will address challenges posed by cyberattacks and the COVID-19 pandemic. Registration is open until January 21, 2022.

Mirion Technologies (NYSE: MIR) has launched the Hyperion™ Compact Digital High Radiation Tolerant Camera, available in color and monochrome versions. This innovative camera enhances digital performance while reducing the cost of ownership, making it ideal for surveillance and high radiation environments, including nuclear power plants. The Hyperion Compact boasts improved durability, significant performance advancements, and a total integrated dose specification of 100 megarads. This development underscores Mirion's commitment to growth in the nuclear power sector.

Mirion Technologies, Inc. (NYSE: MIR) has completed the acquisition of Computerized Imaging Reference Systems, Inc. (CIRS) for approximately $54 million. CIRS specializes in medical imaging and radiation therapy phantoms, crucial for calibrating diagnostic equipment, measuring radiation doses, and ensuring quality assurance in medical settings. This strategic move is expected to enhance Mirion's Medical segment and improve patient outcomes. However, risks exist regarding integration challenges and anticipated benefits may not fully materialize.

Mirion Technologies (NYSE: MIR) reported a 26% increase in GAAP revenues for Q3 2021, totaling $144.3 million, up from $114.6 million in Q3 2020. However, net loss rose 15.8% to ($46.7) million. Adjusted revenues climbed 29% to $148 million, with Adjusted EBITDA at $30.9 million, a 28% increase. The Medical segment saw a significant revenue increase of 155%. Organic growth was a slight (0.1%) compared to 8.5% in the prior year. Mirion completed its business combination with GS Acquisition Holdings Corp II on October 20, 2021, enhancing liquidity to approximately $230 million.

Mirion Technologies (NYSE:MIR) has announced a definitive agreement to acquire Computerized Imaging Reference Systems, Inc. (CIRS) for approximately $54 million. CIRS, based in Norfolk, Virginia, specializes in developing medical imaging and radiation therapy phantoms, projecting Adjusted Revenue of $16 million and Adjusted EBITDA of $5 million for 2022. The acquisition is expected to enhance Mirion's medical segment and improve margins through operational synergies, making it accretive to adjusted EBITDA margins after integration costs. The transaction is slated to close in Q4 2021.

Mirion Technologies (NYSE: MIR) will announce its financial results for the quarter ending September 30, 2021, on November 12, 2021, prior to market opening. A conference call will follow at 8:00 am ET to discuss the results. Participants can join by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (international). A replay will be available until November 26, 2021, accessible at 1-844-512-2921 (U.S.) or 1-412-317-6671 (international). More details are available on Mirion's website.

Mirion Technologies, Inc. (NYSE:MIR) has acquired CHP Dosimetry, a U.S.-based dosimetry services distributor, effective November 1, 2021. CHP Dosimetry, founded in 2004 and located in Clinton, TN, generated $1.2 million in revenue in 2020. This acquisition allows Mirion to serve existing CHP customers directly and leverage CHP's distribution channels for its dosimetry solutions, including the Instadose® platform, improving service efficiency and customer reach.